JP2013010792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013010792A5 JP2013010792A5 JP2012226367A JP2012226367A JP2013010792A5 JP 2013010792 A5 JP2013010792 A5 JP 2013010792A5 JP 2012226367 A JP2012226367 A JP 2012226367A JP 2012226367 A JP2012226367 A JP 2012226367A JP 2013010792 A5 JP2013010792 A5 JP 2013010792A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1cnc2[n]cc(C(N=C(*)*)=NC(*)=I)c2c1 Chemical compound Cc1cnc2[n]cc(C(N=C(*)*)=NC(*)=I)c2c1 0.000 description 20
- PSDSIQPUXJCFBK-UHFFFAOYSA-N C(C1C2)C3C11C4C2C3CC1C4 Chemical compound C(C1C2)C3C11C4C2C3CC1C4 PSDSIQPUXJCFBK-UHFFFAOYSA-N 0.000 description 1
- VVRCYUOEOIOIEK-UHFFFAOYSA-O CC(C(N(C)CC(F)(F)F)=O)Nc1nc(C2=C[NH2+]c3ncccc23)ncc1 Chemical compound CC(C(N(C)CC(F)(F)F)=O)Nc1nc(C2=C[NH2+]c3ncccc23)ncc1 VVRCYUOEOIOIEK-UHFFFAOYSA-O 0.000 description 1
- DZDNCAJEJCQSMR-UHFFFAOYSA-N CC(C)(C)C1N(C)CSC1 Chemical compound CC(C)(C)C1N(C)CSC1 DZDNCAJEJCQSMR-UHFFFAOYSA-N 0.000 description 1
- GDHIUXDCYFUUAE-INIZCTEOSA-N CC(C)[C@@H](NCOCNCC(F)(F)F)Nc1ccnc(-c2c[nH]c3ncccc23)n1 Chemical compound CC(C)[C@@H](NCOCNCC(F)(F)F)Nc1ccnc(-c2c[nH]c3ncccc23)n1 GDHIUXDCYFUUAE-INIZCTEOSA-N 0.000 description 1
- QOVARRUAEFTPOJ-UHFFFAOYSA-O CC(CC1C([NH2+]CC(F)(F)F)=O)(CN1c1nc(-c2c[nH]c3ncccc23)ncc1)F Chemical compound CC(CC1C([NH2+]CC(F)(F)F)=O)(CN1c1nc(-c2c[nH]c3ncccc23)ncc1)F QOVARRUAEFTPOJ-UHFFFAOYSA-O 0.000 description 1
- RJCGAHHUKISJIM-UHFFFAOYSA-N CC(CCC1)(C(NCC(CCF)F)=O)N1c1ccnc(-c2c[nH]c3ncccc23)n1 Chemical compound CC(CCC1)(C(NCC(CCF)F)=O)N1c1ccnc(-c2c[nH]c3ncccc23)n1 RJCGAHHUKISJIM-UHFFFAOYSA-N 0.000 description 1
- GGFKQOQFSGPWBG-UHFFFAOYSA-N CC(NCC(F)(F)F)=O Chemical compound CC(NCC(F)(F)F)=O GGFKQOQFSGPWBG-UHFFFAOYSA-N 0.000 description 1
- MKPZDBNKUJHYCK-UHFFFAOYSA-N CC1N(C)CC1 Chemical compound CC1N(C)CC1 MKPZDBNKUJHYCK-UHFFFAOYSA-N 0.000 description 1
- HPFBCTLYLKRWHC-LJQANCHMSA-N CCCN(C[C@H](C(NCC(F)(F)[F]C)=O)Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(C=C(C)C)=O Chemical compound CCCN(C[C@H](C(NCC(F)(F)[F]C)=O)Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(C=C(C)C)=O HPFBCTLYLKRWHC-LJQANCHMSA-N 0.000 description 1
- RAZUSFPITOYAFO-UHFFFAOYSA-N CCN(CCCCC(NCC(F)(F)F)=O)c1nc(-c2cnc3ncccc23)ncc1F Chemical compound CCN(CCCCC(NCC(F)(F)F)=O)c1nc(-c2cnc3ncccc23)ncc1F RAZUSFPITOYAFO-UHFFFAOYSA-N 0.000 description 1
- CQUBJFQPRYBVRL-MRVPVSSYSA-N C[C@H](C(NCC(F)(F)F)=O)Nc1nc(-c2c[nH]c3ncccc23)ncn1 Chemical compound C[C@H](C(NCC(F)(F)F)=O)Nc1nc(-c2c[nH]c3ncccc23)ncn1 CQUBJFQPRYBVRL-MRVPVSSYSA-N 0.000 description 1
- TYGGIVKWEZXSEO-UHFFFAOYSA-O FC(C[NH2+]CC(CSC1)N1c1nc(-c2c[nH]c3ncccc23)ncc1)(F)F Chemical compound FC(C[NH2+]CC(CSC1)N1c1nc(-c2c[nH]c3ncccc23)ncc1)(F)F TYGGIVKWEZXSEO-UHFFFAOYSA-O 0.000 description 1
- KYSLPFWJGHXTEG-UHFFFAOYSA-O Fc1cnc(C2=C[NH2+]c3ncccc23)nc1N1CCNCC1 Chemical compound Fc1cnc(C2=C[NH2+]c3ncccc23)nc1N1CCNCC1 KYSLPFWJGHXTEG-UHFFFAOYSA-O 0.000 description 1
- DKMRYSYNTIZLMX-UHFFFAOYSA-P NC(CC(C1)F)(C([NH2+]CC(F)(F)F)=O)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1 Chemical compound NC(CC(C1)F)(C([NH2+]CC(F)(F)F)=O)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1 DKMRYSYNTIZLMX-UHFFFAOYSA-P 0.000 description 1
- PGHMUTCFECJKIO-UHFFFAOYSA-P O=C(C(CSC1)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1)[NH2+]CC(F)(F)F Chemical compound O=C(C(CSC1)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1)[NH2+]CC(F)(F)F PGHMUTCFECJKIO-UHFFFAOYSA-P 0.000 description 1
- OLYGQFHFXLFKDY-GFCCVEGCSA-N O=C([C@@H](CC(C1)(F)F)N1c1nc(-c2c[nH]c3ncccc23)ncc1F)NCC(F)(F)F Chemical compound O=C([C@@H](CC(C1)(F)F)N1c1nc(-c2c[nH]c3ncccc23)ncc1F)NCC(F)(F)F OLYGQFHFXLFKDY-GFCCVEGCSA-N 0.000 description 1
- CZCYCVDAGWFZSN-TVQRCGJNSA-N O[C@@H](C[C@@H]1C(NCC(F)(F)F)=O)CN1c1nc(-c2c[nH]c3ncccc23)ncc1F Chemical compound O[C@@H](C[C@@H]1C(NCC(F)(F)F)=O)CN1c1nc(-c2c[nH]c3ncccc23)ncc1F CZCYCVDAGWFZSN-TVQRCGJNSA-N 0.000 description 1
Description
特に明記しない限り、本明細書に示される構造体には、その構造体についての全ての異性体(例、エナンチオマー、ジアステレオマー、及び幾何(又は配座)異性体)の形態、例えば、各非対称中心に対するR及びS配置、(Z)及び(E)二重結合異性体、並びに(Z)及び(E)配座異性体が包含されることを意味する。したがって、本発明の化合物に関する単一の立体化学異性体並びにエナンチオマー、ジアステレオマー、及び幾何(又は配座)異性体混合物は本発明の範囲内である。
Claims (39)
- 式(I)で表される化合物:
(式中、
R 3 は水素であり、
X 1 はN又はCR 4 であり、
R 2 は水素、F、R’、OH、OR’、COR’、COOH、COOR’、CONH 2 、CONHR’、CON(R’) 2 又はCNであり、
R 4 は水素、F、R’、OH、OR’、COR’、COOH、COOR’、CONH 2 、CONHR’、CON(R’) 2 又はCNであるか、又は
R 2 及びR 4 は共に、1〜4個のR 10 で任意に置換されてもよい5−7員のアリール又はヘテロアリール環を形成し、
R’は、1〜4個のR 5 で任意に置換されてもよいC 1−3 脂肪族であり、
各R 5 はハロゲン、CF 3 、OCH 3 、OH、SH、NO 2 、NH 2 、SCH 3 、NCH 3 、CN又は非置換C 1−2 脂肪族から独立に選択されるか、又は2つのR 5 基はそれらが結合する炭素原子と共にシクロプロピル環又はC=Oを形成し、
各R 10 はハロゲン、OCH 3 、OH、NO 2 、NH 2 、SH、SCH 3 、NCH 3 、CN又は非置換C 1−2 脂肪族から独立に選択され、
R 1 は
R”は水素であるか又は1〜3個の−R 11 で任意に置換されてもよい−C 1−2 脂肪族であり、
各R 11 はハロゲン、OCH 3 、OH、SH、NO 2 、NH 2 、SCH 3 、NCH 3 、CN、CON(R 15 ) 2 又は非置換C 1−2 脂肪族から独立に選択されるか、又は2つのR 11 基が、それらが結合する炭素と共にシクロプロピル環又はC=Oを形成し、
R 6 は1〜5個のR 12 で任意に置換されてもよいC 1−4 脂肪族であり、
各R 12 はハロゲン、OCH 3 、OH、NO 2 、NH 2 、SH、SCH 3 、NCH 3 、CN又は非置換C 1−2 脂肪族から独立に選択されるか、又は2つのR 12 基が、それらが結合する炭素と共にシクロプロピル環を形成し、
環Aは、N、O又はSから選択される2つまでのさらなるヘテロ原子を含有し、1〜4個のR 13 で任意に置換されてもよい4〜8員の飽和窒素含有環であり、
各R 13 はハロゲン、R’、NH 2 、NHR’、N(R’) 2 、SH、SR’、OH、OR’、NO 2 、CN、CF 3 、COOR’、COOH、COR’OC(O)R’、又はNHC(O)R’から独立に選択されるか、又は任意の2つのR 13 基が、同じ置換基又は異なる置換基において、各R 13 基が結合している1つ以上の原子と共に、1〜3個のR 5 基で任意に置換されてもよい3〜7員の飽和、不飽和、若しくは部分的に飽和の炭素環若しくは複素環を形成し、
R 14 は水素又は非置換C 1−2 アルキルであり、
R 15 は水素又は非置換C 1−2 アルキルであり、
R 7 は6つまでのFで任意に置換されてもよい、C 2−3 脂肪族若しくは脂環式基である。)。 - R 2 が水素、フッ素、R’、OH又はOR’である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R 2 が水素又はフッ素である、請求項3に記載の化合物又はその薬学的に許容できる塩。
- 前記化合物が式I−Aのものであり、R 4 が水素、フッ素、R’、OH又はOR’であるか、又はR 2 及びR 4 が共に6員のアリール環を形成する、請求項2に記載の化合物又はその薬学的に許容できる塩。
- R 4 が水素又はフッ素である、請求項5に記載の化合物又はその薬学的に許容できる塩。
- R 4 がフッ素であるときR 2 が水素であり、R 2 がフッ素であるときR 4 が水素である、請求項6に記載の化合物又はその薬学的に許容できる塩。
- R 2 及びR 4 が共に水素である、請求項6に記載の化合物又はその薬学的に許容できる塩。
- R 7 がCH 2 CH 3 、CH 2 CF 3 、CH 2 CHF 2 、CH 2 CH 2 F、CH 2 CH 2 CH 3 、CH 2 CH 2 CF 3 、CH 2 CH 2 CH 2 F又はCH 2 CH 2 CHF 2 である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R 7 がCH 2 CH 3 、CH 2 CF 3 、CH 2 CH 2 CH 3 又はCH 2 CH 2 CF 3 である、請求項9に記載の化合物又はその薬学的に許容できる塩。
- R 7 がCH 2 CF 3 である、請求項10に記載の化合物又はその薬学的に許容できる塩。
- R”が水素又はCH 3 である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R”が水素である、請求項12に記載の化合物又はその薬学的に許容できる塩。
- R 14 が水素である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R 15 が水素である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R 13 が存在しない、請求項21に記載の化合物又はその薬学的に許容できる塩。
- 環Aが1つのR 13 で置換されている、請求項21に記載の化合物又はその薬学的に許容できる塩。
- R 13 がOH、CH 3 、F、OR’又はNHR’である、請求項21に記載の化合物又はその薬学的に許容できる塩。
- R’がC 1−2 アルキル又はC 2−3 アルケニルである、請求項25に記載の化合物又はその薬学的に許容できる塩。
- R 13 がOHである、請求項25に記載の化合物又はその薬学的に許容できる塩。
- 患者のJAKキナーゼ活性を阻害するための医薬品組成物であって、請求項1に記載の化合物又はその薬学的に許容できる塩、および薬学的に許容できる担体、補助剤又は賦形剤を含む、医薬品組成物。
- 請求項29に記載の組成物であって、更に、化学療法薬又は抗増殖剤、抗炎症剤、免疫調節剤又は免疫抑制剤、神経栄養因子、心血管疾患を治療するための薬剤、破壊性骨疾患を治療するための薬剤、肝疾患を治療するための薬剤、抗ウィルス薬、血液疾患を治療するための薬剤、糖尿病を治療するための薬剤、又は免疫不全疾患を治療するための薬剤から選択される治療薬を含む、組成物。
- インビトロの生物学的サンプルのJAKキナーゼ活性を阻害する方法であって、請求項1に記載の化合物又はその薬学的に許容できる塩と、前記生物学的サンプルとを接触させることを含む方法。
- R 2 が水素又はフッ素であり、R 4 が水素又はフッ素であり、そしてR 7 がCH 2 CH 3 、CH 2 CF 3 、CH 2 CHF 2 、CH 2 CH 2 F、CH 2 CH 2 CH 2 F、CH 2 CH 2 CH 3 、CH 2 CH 2 CF 3 、CH 2 CH 2 CH 2 F又はCH 2 CH 2 CHF 2 である、請求項1に記載の化合物又はその薬学的に許容できる塩。
- R 2 が水素であり、そしてR 7 がCH 2 CH 3 、CH 2 CF 3 、CH 2 CHF 2 又はCH 2 CH 2 Fである、請求項1または32に記載の化合物又はその薬学的に許容できる塩。
- R 2 が水素であり、R 4 が水素であり、そしてR 7 がCH 2 CF 3 である、請求項1〜28、32または33のいずれか一項に記載の化合物又はその薬学的に許容できる塩。
- R”が水素又はCH 3 であり、R 14 が水素である、請求項1または32〜34のいずれか一項に記載の化合物又はその薬学的に許容できる塩。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75936706P | 2006-01-17 | 2006-01-17 | |
US60/759,367 | 2006-01-17 | ||
US84247106P | 2006-09-06 | 2006-09-06 | |
US60/842,471 | 2006-09-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551353A Division JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014167160A Division JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013010792A JP2013010792A (ja) | 2013-01-17 |
JP2013010792A5 true JP2013010792A5 (ja) | 2014-10-02 |
JP5728454B2 JP5728454B2 (ja) | 2015-06-03 |
Family
ID=38197739
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551353A Expired - Fee Related JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
JP2012226368A Ceased JP2013010793A (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
JP2012226367A Expired - Fee Related JP5728454B2 (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
JP2014167160A Pending JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551353A Expired - Fee Related JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
JP2012226368A Ceased JP2013010793A (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014167160A Pending JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Country Status (19)
Country | Link |
---|---|
US (6) | US7767816B2 (ja) |
EP (3) | EP1973911B1 (ja) |
JP (4) | JP5591471B2 (ja) |
KR (3) | KR101235103B1 (ja) |
CN (3) | CN102532134A (ja) |
AR (1) | AR060316A1 (ja) |
AU (1) | AU2007207533B8 (ja) |
BR (2) | BRPI0706537A2 (ja) |
CA (1) | CA2636189A1 (ja) |
CL (1) | CL2008002140A1 (ja) |
HK (1) | HK1210780A1 (ja) |
IL (1) | IL191902A0 (ja) |
NO (1) | NO20083501L (ja) |
NZ (3) | NZ592968A (ja) |
RU (2) | RU2453548C2 (ja) |
TW (4) | TWI423976B (ja) |
UA (1) | UA95940C2 (ja) |
WO (1) | WO2007084557A2 (ja) |
ZA (2) | ZA200805053B (ja) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2332940T3 (pl) | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
MX2007014619A (es) * | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
BRPI0706537A2 (pt) | 2006-01-17 | 2011-03-29 | Vertex Pharma | azaindóis úteis como inibidores de janus cinases |
MX2008012860A (es) * | 2006-04-05 | 2009-01-07 | Vertex Pharma | Desazapurinas de utilidad como inhibidores de janus cinasas. |
US7754838B2 (en) * | 2006-08-08 | 2010-07-13 | E.I. Du Pont De Nemours And Company | Poly(meth)acrylamides and poly(meth)acrylates containing fluorinated amide |
EP2815750A1 (en) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
CA2681516A1 (en) | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of janus kinases |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
WO2009145814A2 (en) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
AU2009274011B2 (en) * | 2008-07-23 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
RS57869B1 (sr) | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
ME02186B (me) | 2009-12-23 | 2016-02-20 | Takeda Pharmaceuticals Co | Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
WO2011137022A1 (en) * | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Azaindoles as janus kinase inhibitors |
MX2012013194A (es) | 2010-05-20 | 2013-01-22 | Hoffmann La Roche | Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak). |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
CA2822059A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
RU2013132683A (ru) * | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
CA2839937C (en) * | 2011-07-05 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
UA118010C2 (uk) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2854879A1 (en) | 2011-11-07 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
UY34616A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. |
WO2013117649A1 (en) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
PL2830662T3 (pl) * | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
WO2014074471A1 (en) | 2012-11-06 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
WO2014089280A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Alkynyl compounds and methods of use |
WO2014110259A1 (en) | 2013-01-09 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Solid forms of a jak inhibitor |
WO2014113191A1 (en) * | 2013-01-15 | 2014-07-24 | Xiaohu Zhang | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
BR112015023878A2 (pt) * | 2013-03-19 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
WO2014201332A1 (en) * | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
KR20160045070A (ko) | 2013-08-22 | 2016-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 동위원소 풍부 아자인돌 |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
JP6615755B2 (ja) | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
SI3068782T1 (sl) | 2013-11-13 | 2018-10-30 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev v replikacije virusov gripe |
WO2015119126A1 (ja) | 2014-02-04 | 2015-08-13 | 大鵬薬品工業株式会社 | アザインドール誘導体 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
AU2015298876B2 (en) | 2014-08-08 | 2020-02-13 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
NO2721710T3 (ja) | 2014-08-21 | 2018-03-31 | ||
TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
AU2015344740A1 (en) * | 2014-11-10 | 2017-06-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions for Hepatitis C |
JP6460382B2 (ja) * | 2014-11-28 | 2019-01-30 | 株式会社豊田自動織機 | 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質 |
EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
WO2017198122A1 (zh) * | 2016-05-19 | 2017-11-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
CN109843883B (zh) * | 2016-07-26 | 2022-01-14 | 苏州隆博泰药业有限公司 | 作为选择性jak抑制剂化合物,该化合物的盐类及其治疗用途 |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
AU2018257778B2 (en) | 2017-04-24 | 2022-02-17 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CA3106556A1 (en) | 2018-07-27 | 2020-01-30 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
KR102133595B1 (ko) | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
KR102112336B1 (ko) | 2019-08-12 | 2020-05-18 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230151034A1 (en) | 2020-03-17 | 2023-05-18 | Cocrystal Pharma, Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83821A0 (en) | 1986-09-10 | 1988-02-29 | Sandoz Ag | Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
EP0763035A4 (en) | 1994-06-09 | 1997-10-01 | Smithkline Beecham Corp | ENDOTHELIN RECEPTOR ANTAGONISTS |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
FR2784375B1 (fr) * | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
US20030153560A1 (en) | 1999-04-23 | 2003-08-14 | Salituro Francesco G. | Inhibitors of c-Jun N-terminal kinases (JNK) |
JP2003503456A (ja) | 1999-07-02 | 2003-01-28 | スチュアート エイ. リプトン | 神経傷害またはアポトーシスを軽減する方法 |
EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ES2360205T3 (es) | 2001-03-02 | 2011-06-01 | Agennix Ag | Sistema de ensayo de tres híbridos. |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
MXPA04010545A (es) | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida. |
AU2003241925A1 (en) | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
BR0313176A (pt) | 2002-08-02 | 2005-06-14 | Vertex Pharma | Composições de pirazol úteis como inibidores de gsk-3 |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
US7432375B2 (en) | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
PL2332940T3 (pl) | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
KR20070002081A (ko) | 2004-04-02 | 2007-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌 |
US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
US20060122213A1 (en) | 2004-06-30 | 2006-06-08 | Francoise Pierard | Azaindoles useful as inhibitors of protein kinases |
JP2008508303A (ja) | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
WO2006058074A1 (en) | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
KR20070104641A (ko) | 2005-02-03 | 2007-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로 유용한 피롤로피리미딘 |
WO2006124863A2 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
MX2007014619A (es) | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
AU2006297351A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
BRPI0706537A2 (pt) * | 2006-01-17 | 2011-03-29 | Vertex Pharma | azaindóis úteis como inibidores de janus cinases |
CA2641254A1 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
MX2008012860A (es) | 2006-04-05 | 2009-01-07 | Vertex Pharma | Desazapurinas de utilidad como inhibidores de janus cinasas. |
MX2009006345A (es) | 2006-12-14 | 2009-06-23 | Vertex Pharma | Compuestos utiles como inhibidores de proteina cinasa. |
RU2334747C1 (ru) | 2007-04-05 | 2008-09-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
CA2704266A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
WO2009145814A2 (en) | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
CA2854879A1 (en) | 2011-11-07 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
-
2007
- 2007-01-17 BR BRPI0706537-0A patent/BRPI0706537A2/pt not_active IP Right Cessation
- 2007-01-17 NZ NZ59296807A patent/NZ592968A/xx not_active IP Right Cessation
- 2007-01-17 TW TW101137542A patent/TWI423976B/zh not_active IP Right Cessation
- 2007-01-17 JP JP2008551353A patent/JP5591471B2/ja not_active Expired - Fee Related
- 2007-01-17 TW TW102147300A patent/TW201412738A/zh unknown
- 2007-01-17 AR ARP070100199 patent/AR060316A1/es unknown
- 2007-01-17 CN CN2011104033161A patent/CN102532134A/zh active Pending
- 2007-01-17 EP EP07718337.4A patent/EP1973911B1/en active Active
- 2007-01-17 NZ NZ60168707A patent/NZ601687A/en not_active IP Right Cessation
- 2007-01-17 UA UAA200810409A patent/UA95940C2/uk unknown
- 2007-01-17 EP EP20120176813 patent/EP2537849A3/en not_active Withdrawn
- 2007-01-17 TW TW96101771A patent/TWI405761B/zh not_active IP Right Cessation
- 2007-01-17 NZ NZ569899A patent/NZ569899A/en not_active IP Right Cessation
- 2007-01-17 BR BRPI0722364-1A patent/BRPI0722364A2/pt not_active IP Right Cessation
- 2007-01-17 WO PCT/US2007/001225 patent/WO2007084557A2/en active Application Filing
- 2007-01-17 AU AU2007207533A patent/AU2007207533B8/en not_active Ceased
- 2007-01-17 RU RU2008133613/04A patent/RU2453548C2/ru not_active IP Right Cessation
- 2007-01-17 US US11/654,375 patent/US7767816B2/en not_active Expired - Fee Related
- 2007-01-17 KR KR1020127014597A patent/KR101235103B1/ko not_active IP Right Cessation
- 2007-01-17 EP EP20120176810 patent/EP2559694A3/en not_active Withdrawn
- 2007-01-17 CN CN2011103519191A patent/CN102532133A/zh active Pending
- 2007-01-17 KR KR1020087017472A patent/KR101409727B1/ko not_active IP Right Cessation
- 2007-01-17 CA CA 2636189 patent/CA2636189A1/en not_active Abandoned
- 2007-01-17 KR KR1020137005929A patent/KR20130041313A/ko not_active Application Discontinuation
- 2007-01-17 CN CN201510004860.7A patent/CN104650077A/zh active Pending
- 2007-01-17 TW TW101137037A patent/TWI424999B/zh not_active IP Right Cessation
-
2008
- 2008-06-03 IL IL191902A patent/IL191902A0/en unknown
- 2008-06-10 ZA ZA2008/05053A patent/ZA200805053B/en unknown
- 2008-07-21 CL CL2008002140A patent/CL2008002140A1/es unknown
- 2008-08-13 NO NO20083501A patent/NO20083501L/no not_active Application Discontinuation
-
2009
- 2009-04-30 HK HK15111605.7A patent/HK1210780A1/xx unknown
- 2009-06-12 ZA ZA2009/04147A patent/ZA200904147B/en unknown
-
2010
- 2010-05-07 US US12/775,885 patent/US8163917B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 RU RU2011151085/02A patent/RU2011151085A/ru not_active Application Discontinuation
-
2012
- 2012-03-01 US US13/409,702 patent/US8450489B2/en not_active Expired - Fee Related
- 2012-10-11 JP JP2012226368A patent/JP2013010793A/ja not_active Ceased
- 2012-10-11 JP JP2012226367A patent/JP5728454B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-25 US US13/870,173 patent/US8822681B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 US US14/339,514 patent/US9120790B2/en not_active Expired - Fee Related
- 2014-08-20 JP JP2014167160A patent/JP2014210823A/ja active Pending
-
2015
- 2015-07-29 US US14/812,158 patent/US20160008359A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013010792A5 (ja) | ||
JP2013010793A5 (ja) | ||
JP2016509047A5 (ja) | ||
JP2017537940A5 (ja) | ||
PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
JP2014511892A5 (ja) | ||
JP2018515495A5 (ja) | ||
RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
JP2017511360A5 (ja) | ||
JP2015537020A5 (ja) | ||
JP2016530259A5 (ja) | ||
EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
RU2016134751A (ru) | Соединения | |
JP2017531619A5 (ja) | ||
JP2017504635A5 (ja) | ||
RU2011151085A (ru) | Азаиндолы, полезные в качестве ингибиторов янус-киназ | |
RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
JP2019524883A5 (ja) | ||
JP2019510027A5 (ja) | ||
EA201370184A1 (ru) | Гетероарильные производные | |
JP2016519165A5 (ja) | ||
RU2013148146A (ru) | Производные адамантила | |
JP2017524733A5 (ja) | ||
RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
JP2018513832A5 (ja) |